Comparison of the efficacy and safety of 12‐month low‐dose factor VIII tertiary prophylaxis vs on‐demand treatment in severe haemophilia A children

Haemophilia ◽  
2019 ◽  
Author(s):  
Novie A. Chozie ◽  
Fitri Primacakti ◽  
Djajadiman Gatot ◽  
Rahajuningsih D. Setiabudhy ◽  
Angela B. M. Tulaar ◽  
...  
Keyword(s):  
Factor Viii ◽  
Low Dose ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Efficacy And Safety ◽  
On Demand ◽  
Dose Factor

Effect of low‐dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A

Haemophilia ◽  
2020 ◽  
Vol 26 (2) ◽  
pp. 325-332 ◽  
Author(s):  
Nevine Gamal Andrawes ◽  
Manal Hashem Fayek ◽  
Nouran Salah El‐Din ◽  
Raguia Atef Mostafa
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Factor Viii ◽  
Low Dose ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Mineral Density ◽  
Prophylaxis Therapy ◽  
25 Oh Vitamin D ◽  
Dose Factor

A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country

Haemophilia ◽  
2016 ◽  
Vol 22 (3) ◽  
pp. 342-348 ◽  
Author(s):  
S. P. Verma ◽  
T. K. Dutta ◽  
S. Mahadevan ◽  
P. Nalini ◽  
D. Basu ◽  
...  
Keyword(s):  
Factor Viii ◽  
Low Dose ◽  
Randomized Study ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Success Story ◽  
Resource Limited ◽  
Dose Factor

Model‐based evaluation of low‐dose factor VIII prophylaxis in haemophilia A

Haemophilia ◽  
2019 ◽  
Vol 25 (3) ◽  
pp. 408-415 ◽  
Author(s):  
Ari Brekkan ◽  
Johanna Degerman ◽  
Siv Jönsson
Keyword(s):  
Factor Viii ◽  
Low Dose ◽  
Haemophilia A ◽  
Model Based ◽  
Dose Factor

Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A

2008 ◽  
Vol 100 (09) ◽  
pp. 429-434 ◽  
Author(s):  
Olga P. Plyushch ◽  
Tatyana A. Andreeva ◽  
Rosa N. Khametova ◽  
Jack Spira
Keyword(s):  
Factor Viii ◽  
Statistical Significance ◽  
Fixed Dose ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Fixed Amount ◽  
Pegylated Liposomes ◽  
On Demand ◽  
Post Infusion ◽  
The Difference

SummaryPatients with haemophilia A treated prophylactically require frequent factor VIII (FVIII) infusions for bleed protection. Recombinant sucrose-formulated FVIII (rFVIII-FS) with pegylated liposomes (PEGLip-rFVIII-FS) was previously shown to extend the bleed-free period after prophylactic infusion versus rFVIII-FS using two doses of FVIII with a fixed amount of liposomal diluent. This randomised, subject-blinded, four-way crossover study evaluated the efficacy and safety of PEGLip-rFVIII-FS using various quantities of pegylated liposomes with a fixed FVIII dose. Adults with severe haemophilia A were randomised to one of four treatment arms. Each arm had four treatment segments, with each segment consisting of a prophylactic infusion followed by on-demand infusions. The prophylactic infusions used a fixed dose of 35 IU/kg rFVIII-FS, but varied in the amount of pegylated liposomes used for reconstitution (4.2, 12.6, or 22.1 mg/kg of body weight or water as a control). On-demand infusions all used 35 IU/kg rFVIII-FS. After treatment of spontaneous bleeds and a wash-out, subjects crossed to another treatment segment (i.e. another PEGLip-rFVIII-FS dose or control).Sixteen subjects enrolled in and completed the study. Mean number of bleed-free days after prophylactic infusion increased from 7.8 days for control rFVIII-FS to 8.7, 10.8, and 10.9 days for PEGLip-rFVIII-FS reconstituted in 4.2, 12.6, and 22.1 mg/kg of pegylated liposomes, respectively. The difference in bleed-free days approached but did not achieve statistical significance in this small study population. No drug-related adverse events or inhibitors were reported. This study helps establish the optimal concentration of liposomes in PEGLip-rFVIII-FS to prolong the post-infusion bleed-free period.

Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings

2015 ◽  
Vol 114 (10) ◽  
pp. 676-684 ◽  
Author(s):  
Laszlo Nemes ◽  
Victor Jimenez-Yuste ◽  
Luminita Rusen ◽  
Ana Cid ◽  
Robert Charnigo ◽  
...  
Keyword(s):  
Factor Viii ◽  
Clinical Manifestations ◽  
Surveillance Study ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Inhibitor Development ◽  
On Demand ◽  
Fviii Inhibitor ◽  
Increased Risk ◽  
Clinically Significant

SummaryThis prospective, open-label, postauthorisation safety surveillance study assessed clinically significant inhibitor development in patients with severe haemophilia A transitioning from moroctocog alfa or other factor VIII (FVIII) replacement products to reformulated moroctocog alfa (AF-CC). Males aged12 years with severe haemophilia A (FVIII:C) < 1 IU/dl), > 150 exposure days (EDs) to recombinant or plasma-derived FVIII products, and no detectable inhibitor at screening were enrolled. Primary end point was the incidence of clinically significant FVIII inhibitor development. Secondary end points included annualised bleeding rate (ABR), less-than-expected therapeutic effect (LETE), and FVIII recovery. Patients were assigned to one of two cohorts based on whether they were transitioning to moroctocog alfa (AF-CC) from moroctocog alfa (cohort 1; n=146) or from another recombinant or plasma-derived FVIII product (cohort 2; n=62). Mean number of EDs on study was 94 (range, 1–139). Six positive FVIII inhibitor results, as determined by local laboratories, were reported in four patients; none were confirmed by a central laboratory, no inhibitor-related clinical manifestations were reported, and all anti-FVIII antibody assays were negative. Median ABRs were 23.4 and 3.4 in patients categorised at baseline as following on-demand and prophylactic regimens, respectively; 86.5 % of bleeding episodes resolved after one infusion. LETE incidence was 0.06 % and 0.19 % in the on-demand and prophylaxis settings, respectively. FVIII recovery remained constant throughout the study. No new safety concerns were identified. This study found no increased risk of clinically significant FVIII inhibitor development in patients transitioning from moroctocog alfa or other FVIII replacement products to moroctocog alfa (AF-CC).

Secondary prophylaxis in an adult patient with severe haemophilia A

2013 ◽  
Vol 33 (03) ◽  
pp. 241-244 ◽  
Author(s):  
C. Schubert ◽  
S. Schlenkrich
Keyword(s):  
Factor Viii ◽  
Prospective Studies ◽  
Primary Prophylaxis ◽  
Secondary Prophylaxis ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Bleeding Rate ◽  
On Demand ◽  
Optimal Dosing ◽  
Joint Protection

SummaryPrimary prophylaxis has been proven as the gold standard for preserving joint function in severe haemophilia. Secondary prophylaxis in children has also been shown to have a more beneficial effect on joint protection as on-demand treatment. The outcome of delayed secondary prophylaxis started in adulthood is rarely studied. The case of a man (age: 47 years) with severe haemophilia A demonstrates the successful switch from on-demand therapy to prophylaxis with sub-sequent reduction of annual bleeding rate and number of days of work lost. The small increase of factor VIII consumption (16%) and the decrease of bleeding rate are compared with data from two recently published prospective studies.An optimal dosing schedule needs to be discussed and larger and longer prospective studies targeting the benefits of secondary prophylaxis with factor VIII started in adulthood are necessary.

Sign in / Sign up

Export Citation Format

Share Document